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Aim: The purpose of this study was to assess if the P21 nt590 polymorphism is associated with the susceptibility to nasopharyngeal 
cancer and with the age at diagnosis. Materials and Methods: We analyzed the frequency of 3’UTR P21 polymorphisms in blood 
samples from 102 nasopharyngeal cancer patients and 191 controls, with no known oncologic disease, using PCR–RFLP. Results: 
The polymorphism genotype frequencies were 93.2% (CC), 5.2% (CT) and 1.6% (TT) in the control group and 88.2% (CC), 10.8% 
(CT) and 1.0% (TT) in the cases group. We found no statistically significant association between the different P21 polymorphism 
genotypes and risk of nasopharyngeal cancer (p = 0.201). However, approximately a four-fold increased risk of undifferentiated 
nasopharyngeal carcinoma in early stages was observed for P21 T carriers (OR = 3.734; 95% IC 1.289–10.281; p = 0.01). Fur-
thermore, our results indicate that the waiting time for onset of neoplasia in T carriers patients was 12.4 years earlier (56.5 years 
old), comparing with those carrying CC genotype (68.9 years old). Conclusions: Our findings suggest that the 3’UTR P21 poly-
morphism may play an important role in the pathogenesis and initiation, but not in the progression, of undifferentiated nasopha-
ryngeal carcinoma. Moreover, the polymorphism seems to contribute to a significantly earlier age at diagnosis.
Key Words: genetic polymorphisms, nasopharyngeal cancer, P21.
Nasopharyngeal cancer is usually a multifactorial 
disease and genetic susceptibility has a crucial role 
in the etiology of this pathology, as well as environ-
mental, viral and dietetic factors.
The p211WAF1/Cip1 protein belongs to the Cip/Kip 
family of cyclin-kinase inhibitors (CKI). It is also known 
as CIP1 (CDK-interacting protein 1) or WAF1 (wild-type 
p53-activated fragment 1), as p21 protein expression 
is usually regulated by p53 protein transcriptional le-
vels [1, 2]. In fact, a possible change in TP53 tumor 
suppressor gene (found in 50% of all tumors) will 
prevent gene P21 transcription and G1 cell cycle ar-
rest, thus allowing continuous activity of cyclin-CDK 
complexes and autonomous proliferating capacity.
The p21 protein is codified by gene P21 and it is lo-
calized on chromosome 6 (6p21.2). This gene consists 
of 3 exons (68, 450 e 1600 pb), but the first one is not 
transcribed. p21 protein has a preferential nuclear 
location, containing 164 amino acids, with a molecular 
weight of 21 kDa [3]. It has cell cycle regulation func-
tions, inhibiting CDKs in G1/S and G2/M. The p21 pro-
tein binds to cyclin-CDK complexes, inhibiting phos-
phorylation of the retinoblastoma protein [4]. Thus, 
the activity of E2F transcription factor is blocked and 
cell cycle arrests in G1/S transition [5, 6]. In different 
studies it was concluded that it promotes or inhibits 
apoptosis and differentiation [7–9].
The CIP/KIP family (p21, p27 and p57) has similari-
ties in the amino terminal of its structure. The amino 
terminal of these proteins is necessary and sufficient 
to inhibit the activity of cyclin-CDK complex. The car-
boxyl terminal of p21 is associated with proliferating 
cell nuclear antigen (PCNA), interlinked with tumor 
growth suppression through inhibition of PCNA depen-
dant replication [10]. It also has a nuclear localization 
signal (NLS) [3] proximal to that terminal.
P21 mutations are rare in neoplasia [11], but a decrease 
in expression is usually associated with worse prognosis 
in humans [12, 13]. It is therefore possible that the carci-
nogenesis process is potentiated by genetic variations 
in P21 gene that affect the expression of p21 protein.
The aim of this study was to investigate 
if the P21 nt590 polymorphism is associated with the sus-
ceptibility for nasopharyngeal cancer and with the age 
at diagnosis.
MATERIALS AND METHODS
Population. A case-control study was carried out 
to assess the possible association between the pre-
sence of the polymorphism and susceptibility for 
nasopharyngeal cancer.
Samples were collected from 102 patients with na-
sopharyngeal cancer, admitted and treated at the Por-
tuguese Institute of Oncology, Porto, Portugal (median 
age 47.5 years, SD 3.90 years). The control group con-
sisted of 191 healthy volunteers without clinical history 
of cancer (median age 55.7 years, standard deviation 
15 years). Histological type and grade of tumors are 
presented in Table 1.
All blood samples were collected after informed 
consent, according to the Declaration of Helsinki, 
and after local ethics committee approval at the Por-
tuguese Institute of Oncology. Du ring laboratory pro-
ceedings, the clinical status and outcome of patients 
was not known by the investigators.
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Samples. Blood samples were collected in EDTA 
containing tubes. Genomic DNA was extracted from 
the white blood cell fraction of each case, using Qia-
gen® extraction kit, Qiamp DNA Mini Kit.
P21CIP1/WAF1 exon 3 genotype analysis. Amplifi-
cation of a 300 bp DNA fragment was obtained after 
a polymerase chain reaction-restriction fragment 
length polymorphism (PCR-RFLP) method adapted 
from a previously described protocol [14]. The pri-
mers used were E3A: 5’ CCC AGG GAA GGG TGT 
CCT G-3’ and E3B: 5’GGG CGG CCA GGG TAT GTA 
C-3’. DNA was amplified in a 50 μl mixture including 
1xTaq Buffer, 1.5 mM MgCl2, 0,2 nM deoxynucleotide 
triphosphates, 0.3 μM from each primer, and 1 Unit 
Taq DNA polymerase. Thermocycler parameters were 
as follows: 94 oC for 5 min, 30 cycles of 94 oC for 60 s, 
60 oC for 45 s and 72 oC for 60 s, and a final extension 
step at 72 oC for 5 min. The 300 bp fragment, veri-
fied by electrophoresis on a 1.5% agarose gel, was 
digested overnight at 37 oC with 1 Unit of PstI enzyme. 
This enzyme recognizes the CT polymorphism leading 
to the loss of a PstI site. In the presence of the C al-
lele, two fragments of 174 and 126 bp were expected. 
The restriction-digested products were analyzed 
by electrophoresis in 2% agarose gel stained with 
ethidium bromide and visualized under UV light.
Finally, we considered a basic question: “For 
a newborn individual, what is the probability that he will 
experience onset of advanced disease before the age 
of X, supposing he survives that long?”, assuming that 
all cases were at an identical risk of nasopharyngeal 
cancer at birth [15]. To address this question, we hy-
pothesized that nt590 P21 genotypes may alter the on-
set of these cancers. We deﬁne the age of the onset 
for cancer as the outcome and nt590 P21 genotype 
as an independent variable.
Statistical analysis. Data analysis was performed 
using the computer software Statistical Package for 
Social Sciences — Version 15.0, SPSS Inc, 2004.
Chi-square analysis was used to compare cate-
gorical variables. A 5% level of significance was used 
in the analysis. The odds ratio (OR) and its 95% con-
fidense interval (CI) were calculated as a measurement 
of the association between P21 genotypes and NPC 
risk. The Hardy — Weinberg equilibrium was tested 
by a Pearson goodness of ﬁt test to compare the ob-
served versus the expected genotype frequencies.
We tested the association between age of onset 
and the polymorphism genotype by comparing Ka-
plan — Meier survival curves. We therefore considered 
the  waiting time for onset of disease (WTOD) as the in-
terval between the time of initial exposure to the risk 
factor (polymorphism) and the time of onset of disease. 
We estimated the cumulative probabilities for having 
cervical and nasopharyngeal cancers by the Ka-
plan — Meier methodology. The primary analysis 
of time-to-event for WTOD was performed with the use 
of two-sided log-rank test at the 5% level of statistical 
signiﬁcance.
RESULTS
We analyzed P21 3’ UTR genotypes in 102 cases 
of nasopharyngeal cancer and 191 healthy volunteers 
using the PCR-RFLP method. Clinicopathological 
information is described in Table 1.
Table 1. Clinicopathological characteristics of nasopharyngeal carcinoma 
patients and control group
Cases Controls
n = 102 n = 191
Gender n (%) n (%)
Male 75 (73.5) 145 (75.9)
Female 27 (26.5) 46 (24.1)
Total 102 (100.0) 191 (100.0)
Age
Mean 47.49 55.68
Standard deviation 14.966 3.904
Median 50 56
Histological type
Undifferentiated 100 (98) -
Other 2 (2) -
Stage
I 1 (1.0) -
II 27 (26.4) -
III 29 (28.4) -
IV 40 (39.2) -
Unknown 5 (4.9) -
Total 102 (100.0) -
Regarding histology, 98% of cases were undif-
ferentiated carcinomas and polymorphism analysis 
was performed in these cases. According to clinical 
stages, stage I represented 1%, stage II — 26.4%, 
stage III —28.4% and 39.2% were stage IV. Genotype 
frequencies in the controls group were 93.2% (CC), 
5.2% (CT) and 1.6% (TT). In nasopharyngeal cancer 
88.2% patients presented CC genotype, 10.8% were 
heterozygous (CT) and 1.0% presented TT genotype 
(Table 2).
Table 2. Genotype frequencies of nt590 P21 polymorphism and risk for 
nasopharyngeal cancer
Genotype
CC CT TT
Recessive Model
T-Car-
rier OR 95% CI p
N (%) N (%) N (%) N (%)
Controls 
n = 191
178 
(93.2)
10 (5.2) 3 (1.6) 13 (6.8) 1 Refer-
ence
Cases 
n = 102
90 
(88.2)
11 (10.8) 1 (1.0) 12 
(11.8)
1.826 0.800– 
4.164
0.148
Undifferenti-
ated n = 100
88 
(88.0)
11 
(11.0)
1 (1.0) 12 
(12.0%)
1.867 0.818– 
4.261
0.133
No association was found between the presence 
of the genotypes studied and risk for the development 
of nasopharyngeal cancer. A statistically significant as-
sociation was found between the presence of T allele 
and cancer susceptibility in the early stages, with T al-
lele carriers presenting a four-fold increase in the risk 
for the development of nasopharyngeal cancer (OR = 
3.734; 95%IC 1.289–10.281; p = 0.01) (Table 3). This 
association was not found for more advanced stages.
Table 3. Analysis regarding the susceptibility of T allele carriers to the de-
velopment of undifferentiated histologic type of nasopharyngeal carcino-
ma, according to the tumor stage
CC CT/TT
OR T-car-
rier geno-
type
95% CI p (χ2 test)
Controls 178 (93.2%) 13 (6.8%) — — —
Stages I and II 22 (78.6%) 6 (21.4%) 3.734 1.289–10.821 0.01
Stages III and IV 63 (91.3%) 6 (8.7%) 1.304 0.475–3.577 0.605
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For early stages, the estimated average for T allele 
carriers was 56.5 years, and 68.9 years for CC genotype.
Figure shows the Kaplan — Meier curves relating 
to the WTOD for undifferentiated nasopharyngeal can-
cer, stages I and II. The log-rank test was used to com-
pare the curves, with a confidence interval of 95%. This 
curve shows that T allele carriers present a trend for 
developing undifferentiated nasopharyngeal cancer 
(stages I and II) in earlier ages than patients without 
the same allele (log-rank test: p = 0.001).
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Figure. Association between CC or T carrier (CT/TT) genotypes and 
the waiting time to onset of disease (WTOD) for stages I and II un-
differentiated histologic type of nasopharyngeal carcinoma group
For more advanced stages (III–IV), the average 
was 57.7 years for allele T carriers, and 61.9 years 
for CC genotype. These values do not show statisti-
cally significant differences (log-rank test: p = 0.529), 
Therefore, there is no association between the geno-
type of the polymorphism and risk for undifferentiated 
nasopharyngeal cancer in more advanced stages.
DISCUSSION
It is now accepted that p21 protein is a univer-
sal inhibitor of CDKs, preventing phosphorylation 
of the retinoblastoma protein, promoting cell cycle 
arrest in G1/S. It also induces normal and tumor cell 
differentiation, promotion/inhibition of apoptosis, inhibi-
tion of DNA replication by binding with PCNA and repair 
functions, especially those mediated by p53. P21 gene 
expression is regulated by protein p53 with increased 
levels in genotoxic stress situations leading to cell cycle 
arrest or cell death [16–18]. Several studies associated 
changes in this gene with carcinogenesis. Most of these 
studies involve changes in protein expression levels, 
but several authors focused on the impact of different 
gene polymorphisms in the carcinogenesis process 
of different cancers, such head and neck, oral cavity 
or nasopharynx cancer [19–25] (Table 4).
It has been established that some genetic varia-
tions in P21 gene such as polymorphisms can be asso-
ciated with different levels of susceptibility for cancer. 
Few studies are available for nasopharyngeal cancer.
Table 4. Studies on the association between P21 gene polymorphisms 
and risk of head and neck, oral cavity and nasopharyngeal cancer
Reference Year Country Cancer Type Polymorphism Association
Sun et al. 1995 China Nasopharynx Ser31Arg No
Ralhan et al. 2000 India Oral Cavity Codon 149 Yes
Tsai et al. 2002 China Nasopharynx Ser31Arg No
Li et al. 2005 USA Head and Neck Ser31Arg Yes
Bau et al. 2007 China Oral Cavity Ser31Arg Yes
Gomes et al. 2008 Brasil Oral Cavity Ser31Arg Yes
Lei et al. 2010 USA Head and Neck Ser31Arg Yes
The nt590 polymorphism of gene P21, commonly 
associated with codon 31 polymorphism [26], is  located 
in the 3’ UTR region (non transcribed region), that 
is associated with cell differentiation and proliferation 
as well as tumor and metastatic suppression, because 
it is frequently related to mRNA stability and degradation 
[27, 28]. Therefore, although this polymorphism is not 
included in a transcription region, it can increase sus-
ceptibility for cancer, when causing functional changes 
in the protein and the cell cycle [29].
In our study, no direct association was found be-
tween nt590 P21 polymorphism genotypes and the risk 
to nasopharyngeal cancer. Nevertheless, a significant 
association was found between onset of the disease 
and the polymorphism with T allele carriers (CT and 
TT genotypes) presenting a four-fold higher risk for 
the deve lopment of undifferentiated carcinoma in early 
stages when compared with wild-type (CC) allele carriers. 
This association was not observed for advanced stages 
of the disease, thus suggesting the relevant role of the 
polymorphism in the initial stage of carcinogenesis rather 
than in disease progression, or in less aggressive subtypes 
of the neoplasia. Additionally, individuals carrying the risk 
genotype (CT and TT genotypes) are younger at the time 
of diagnosis, thus supporting the possible role of the poly-
morphism as a genetic determinant in the pathogenesis 
of undifferentiated nasopharyngeal carcinoma.
The genetic association between gene P21 poly-
morphism and undifferentiated nasopharyngeal car-
cinoma is biologically plausible. This particular his-
tological type of cancer is associated with EBV 
[30–32]. With p21 unchanged, cell proliferation is in-
hibited but it is possible that the presence of T allele 
in nt590 of gene P21 changes protein function. This 
would prevent the B7-H4 cellular protein-induction 
of G0/G1 cell block, which occurs after EBV infec-
tion [33], and therefore perpetuating cell division 
and contributing to a cancer phenotype. In the same 
way, the change from allele C to T in nt590 may lead 
to a change in the p21 function, decreasing the ef-
ficacy of apoptosis-induced by BRLF1 viral protein 
and mediated by E2F1 transcription factor [33]. These 
points towards the possible impact of polymorphism 
in nt590 in the initiation stage of the disease, a time in-
timately related to uncontrolled proliferation triggered 
by EBV induced cell cycle abnormalities.
P21 expression is high in genotoxic stress situations 
induced by an increase in p53 levels, leading to cell 
cycle arrest or cell death. In fact, genotoxic stress is one 
of the characteristics of viral infections, such as EBV 
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infections, primarily due to the increase of oxygen 
and nitrogen reactive species [16–18]. This corrobo-
rates the possibility of nt590 polymorphism potentiate 
the onset of the disease in undifferentiated nasopha-
ryngeal carcinoma, associated with EBV, in relation to all 
the changes in cell cycle key proteins resulting from 
this infection. The association between nt590 polymor-
phism and the risk for undifferentiated nasopharyngeal 
carcinoma in early stages allows us to hypothesize that 
T allele can function as a promoter for the initiation 
stage of the neoplasia. Other factors related to tumor 
microenvironment may exist that define the evolution 
of the neoplasia. Alternatively, the presence of T allele 
in this polymorphism may be related with less tumor ag-
gressiveness, originating an increased number of T allele 
carriers in the less aggressive early stages of the disease.
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